Article

Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial

Klinik für Anästhesiologie der Technischen Universität München, Munich, Germany.
European Journal of Anaesthesiology (Impact Factor: 3.01). 10/2010; 27(10):874-81. DOI: 10.1097/EJA.0b013e32833d56b7
Source: PubMed

ABSTRACT Sugammadex, a modified gamma-cyclodextrin, is a selective relaxant-binding agent designed to reverse the effects of the steroidal neuromuscular blocking agents rocuronium or vecuronium. This study compared the efficacy of sugammadex and neostigmine for reversal of neuromuscular blockade induced by rocuronium for facilitating elective surgery.
This randomised, multicentre, parallel-group trial included 98 adult patients. Patients received intravenous propofol for induction followed by sevoflurane maintenance anaesthesia. Neuromuscular blockade was monitored using acceleromyography and a train-of-four (TOF) mode of stimulation. Patients were randomly allocated to receive sugammadex 2.0 mg kg(-1) or neostigmine 50 microg kg (-1) (with glycopyrrolate 10 microg kg(-1)) at reappearance of the second response of the TOF (mean 16% twitch height of first response) after the last dose of rocuronium. Safety was evaluated by assessing adverse events, laboratory variables and vital signs.
Time to recovery of the TOF ratio of 0.9 after sugammadex compared with neostigmine was significantly shorter (P < 0.0001), being 1.5 versus 18.6 min (geometric means). Predictability of response was greater with sugammadex than neostigmine: with 98% of sugammadex patients versus 11% of neostigmine patients recovering to a TOF ratio of 0.9 within 5 min. There were no clinical events related to residual neuromuscular blockade or reoccurrence of blockade. Serious adverse events were observed in two sugammadex-treated patients and in three neostigmine-treated patients, respectively, but none were considered related to study drugs.
Sugammadex achieved significantly faster recovery of neuromuscular function after rocuronium to a TOF ratio of 0.9 compared with neostigmine (Clinicaltrials.gov identifier: NCT00451217).

1 Follower
 · 
116 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether the new selective binding agent sugammadex causes less postoperative nausea and vomiting (PONV) than the cholinesterase inhibitor neostigmine. Prospective, randomized, double-blinded study. University-affiliated hospital. One hundred American Society of Anesthesiologists physical status 1 and 2 patients scheduled for extremity surgery. Patients were randomly assigned to neostigmine (70 μg/kg) and atropine (0.4 mg per mg neostigmine) or sugammadex 2 mg/kg for neuromuscular antagonism at the end of anesthesia, when 4 twitches in response to train-of-four stimulation were visible with fade. We recorded PONV, recovery parameters, antiemetic consumption, and side effects. Nausea and vomiting scores were lower in the sugammadex patients upon arrival in the postanesthesia care unit (med: 0 [min-max, 0-3] vs med: 0 [min-max, 0-3]; P < .05), but thereafter low and comparable. Postoperative antiemetic and analgesic consumption were similar in each group. Extubation (median [interquartile range], 3 [1-3.25] vs 4 [1-3.25]; P < .001) first eye opening (4 [3-7.25] vs 7 [5-11]; P < .001), and head lift (4 [2-7.25] vs 8 [11-25]; P < .001) in minutes were shorter in patients given sugammadex. Postoperative heart rates were significantly lower in all measured times patients given neostigmine. Nondepolarizing neuromuscular blocking antagonism with sugammadex speeds recovery of neuromuscular strength but only slightly and transiently reduces PONV compared with neostigmine and atropine. Copyright © 2014 Elsevier Inc. All rights reserved.
    Journal of Clinical Anesthesia 12/2014; 27(1). DOI:10.1016/j.jclinane.2014.08.010 · 1.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Die bronchopulmonale Aspiration ist eine weit gefürchtete Komplikation in der Anästhesie. Ihre Inzidenz wird mit etwa 0,3–1% angegeben, und sie geht mit deutlich erhöhter Morbidität sowie Mortalität einher (Beck-Schimmer u. Bonvini, Eur J Anaesthesiol 2011, 28:78–84). Die „rapid sequence induction“ (RSI, Notfalleinleitung) stellt das Verfahren der Wahl zur Narkoseeinleitung des aspirationsgefährdeten Patienten dar. Seit mittlerweile über 50 Jahren gilt bei der RSI Succinylcholin aufgrund seiner kurzen Anschlagszeit und kurzer Wirkdauer als Relaxans der Wahl. Im Hinblick auf das ausgeprägte Nebenwirkungsprofil von Succinylcholin wurde versucht, besser geeignete, alternative Relaxanzien, wie beispielsweise Rocuronium zur RSI einzusetzen. Material und Methode In einer kleinen Fallserie wurde im Rahmen von Sectiones im Kreißsaal bei 10 Schwangeren ein modifiziertes RSI-Protokoll verwendet. Dieses beinhaltete zur Einleitung der Muskelrelaxation die Gabe von 1,0 mg/kgKG Rocuronium und die Aufrechterhaltung einer tiefen Relaxierung bis zum Ende der Operation. Zur Reversierung der neuromuskulären Blockade nach Beendigung der Hautnaht wurde das µ-Zyklodextrin Sugammadex, in einer Dosierung abhängig von der Tiefe der neuromuskulären Restblockade, appliziert. Neben den Intubationsbedingungen nach 60 s wurden Nebenwirkungen wie Herzrhythmusstörungen, Heiserkeit, anaphylaktische Reaktionen, postoperative Übelkeit und Erbrechen postoperativ, nach 24 und 48 h erfragt sowie dokumentiert. Schlussfolgerungen Die Kombination von Rocuronium und Sugammadex zur RSI im Rahmen von Sectiones im Kreißsaal vereint neben den Vorteilen der nichtdepolarisierenden Eigenschaften des Rocuroniums schnelle Anschlagszeiten, sehr gute Intubationsbedingungen und die rasche Reversierung durch Sugammadex am Operationsende. Schwerwiegende Nebenwirkungen wurden nicht beobachtet. Heiserkeit sowie Halsschmerzen beklagten 30% und Muskelschmerzen 10% der untersuchten Frauen bis 48 h nach dem Eingriff.
    Der Anaesthesist 08/2012; 61(8). DOI:10.1007/s00101-012-2065-6 · 0.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sugammadex belongs to a new class of drug: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non-depolarizing muscle relaxants. The main advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However, it only works for reversal of rocuronium- or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium, the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine. Compared with neostigmine, reversal cost is significantly higher. However, economic aspects must take into account the reduction in recovery time and, more importantly, the prevention of residual paralysis in the PACU that can induce critical respiratory events and postoperative pulmonary complications.
    06/2013; 3(2). DOI:10.1007/s40140-013-0015-8